HC Wainwright Issues Positive Outlook for NovoCure Earnings

NovoCure Limited (NASDAQ:NVCR) – Investment analysts at HC Wainwright lifted their Q4 2025 earnings estimates for shares of NovoCure in a report issued on Tuesday, January 13th. HC Wainwright analyst E. Bodnar now expects that the medical equipment provider will post earnings per share of ($0.30) for the quarter, up from their prior forecast of ($0.31). HC Wainwright has a “Buy” rating and a $39.00 price objective on the stock. The consensus estimate for NovoCure’s current full-year earnings is ($1.30) per share. HC Wainwright also issued estimates for NovoCure’s Q1 2026 earnings at ($0.34) EPS, Q2 2026 earnings at ($0.37) EPS, Q3 2026 earnings at ($0.39) EPS, Q4 2026 earnings at ($0.40) EPS, FY2026 earnings at ($1.49) EPS, FY2027 earnings at ($1.08) EPS, FY2028 earnings at ($0.34) EPS and FY2029 earnings at $1.07 EPS.

Other research analysts have also issued research reports about the company. JPMorgan Chase & Co. reduced their price target on NovoCure from $25.00 to $23.00 and set a “neutral” rating on the stock in a report on Monday, October 27th. Evercore ISI set a $20.00 price objective on shares of NovoCure in a research report on Monday, January 5th. Weiss Ratings reiterated a “sell (e+)” rating on shares of NovoCure in a report on Wednesday, October 8th. Finally, Wedbush reissued a “neutral” rating and issued a $18.00 price target on shares of NovoCure in a research note on Tuesday, September 30th. Three research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, NovoCure currently has a consensus rating of “Hold” and an average price target of $25.50.

NovoCure Stock Performance

NASDAQ NVCR opened at $13.77 on Thursday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.50 and a current ratio of 1.55. The stock’s fifty day moving average is $12.66 and its two-hundred day moving average is $13.22. The firm has a market capitalization of $1.54 billion, a P/E ratio of -8.55 and a beta of 0.73. NovoCure has a fifty-two week low of $10.70 and a fifty-two week high of $27.70.

NovoCure (NASDAQ:NVCR) last posted its quarterly earnings results on Thursday, October 30th. The medical equipment provider reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.09. NovoCure had a negative return on equity of 50.29% and a negative net margin of 27.66%.The firm had revenue of $167.20 million during the quarter, compared to analysts’ expectations of $158.81 million. During the same quarter last year, the firm earned ($0.28) earnings per share. The business’s revenue for the quarter was up 7.8% on a year-over-year basis.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Strs Ohio purchased a new position in shares of NovoCure in the first quarter valued at approximately $759,000. KLP Kapitalforvaltning AS lifted its holdings in NovoCure by 6.5% during the 2nd quarter. KLP Kapitalforvaltning AS now owns 23,000 shares of the medical equipment provider’s stock worth $409,000 after buying an additional 1,400 shares in the last quarter. Washington Capital Management Inc. purchased a new position in NovoCure in the 2nd quarter valued at approximately $374,000. American Century Companies Inc. grew its stake in shares of NovoCure by 1,354.7% in the second quarter. American Century Companies Inc. now owns 1,029,874 shares of the medical equipment provider’s stock worth $18,332,000 after acquiring an additional 959,079 shares in the last quarter. Finally, Jump Financial LLC purchased a new stake in shares of NovoCure during the second quarter worth $6,268,000. Hedge funds and other institutional investors own 84.61% of the company’s stock.

Key Headlines Impacting NovoCure

Here are the key news stories impacting NovoCure this week:

• Positive Sentiment: HC Wainwright retained a “Buy” rating and set a $39 price target (reduced from $42), implying substantial upside from today’s price and likely supporting buying interest. Read More.
• Positive Sentiment: HC Wainwright published a long‑term outlook (FY2030 EPS of $3.28), signaling confidence in a recovery/outperformance over the next several years and giving investors a positive long‑term thesis to balance nearer‑term cuts. Read More.
• Neutral Sentiment: Management presented at the J.P. Morgan Healthcare Conference; the transcript provides operational and clinical updates that investors will parse for growth cadence and commercialization progress. Read More.
• Neutral Sentiment: Aggregate analyst coverage shows a mixed view — a recent report summarized a consensus rating around “Hold,” which may temper directional conviction despite pockets of bullishness. Read More.
• Negative Sentiment: HC Wainwright trimmed multiple near‑term and multi‑year EPS estimates (Q1–Q4 2026 and FY2026–FY2029), increasing expected losses in the near term (for example, FY2026 EPS was lowered to around -$1.49 from -$1.39). Those cuts weaken short‑term earnings visibility and are downside pressure for the stock. Read More.
• Negative Sentiment: A Seeking Alpha article questions NovoCure’s ability to disrupt non‑small cell lung cancer (NSCLC), highlighting clinical and market‑share challenges; negative narrative risk on therapy adoption could weigh on growth expectations if concerns persist. Read More.

About NovoCure

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.